83 4 CHEMOTHERAPY-INDUCED NAUSEA AND VOMITING | PART TWO 17. Vardy J, Chiew KS, Galica J et al. Side-effects associated with the use of dexamethasone for prophylaxis of delayed emesis after moderately emetogenic chemotherapy. Br J Cancer 2006;94:1011-5. 18. Celio L, Bonizzoni E, Zattarin E et al. Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC cancer 2019;19:1268. 19. Celio L, Frustaci S, Denaro A et al. Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. Support Care Cancer 2011;19:1217-25. 20. Komatsu Y, Okita K, Yuki S et al. Openlabel, randomized, comparative, phase III study on effects of reducing steroid use in combination with palonosetron. Cancer Sci 2015;106:891-5. 21. Singh P, Yoon SS, Kuo B. Nausea: a review of pathophysiology and therapeutics. Therap Adv Gastroenterol 2016;9:98-112. 22. Wickham RJ. Revisiting the physiology of nausea and vomiting-challenging the paradigm. Support Care Cancer 2020;28:13-21. 23. Andrews PLR, Sanger GJ. Nausea and the quest for the perfect anti-emetic. Eur J Pharmacol 2014;722:108-21. 24. Martin AR, Pearson JD, Cai B et al. Assessing the impact of chemotherapyinduced nausea and vomiting on patients’ daily lives: a modified version of the Functional Living Index-Emesis (FLIE) with 5-day recall. Support Care Cancer 2003;11:522-7. 25. Guy W. ECDEU assessment manual for psychopharmacology-revised (DHEW publication number ADM 76338) Rockville, MD, US Department of Health, Education and Welfare, Public Health Service, Alcohol, Drug Abuse and Mental Health Administration, NIMH Psychopharmacology Research Branch, Division of Extramural Research Programs, 1976:534-7. 26. Schnell FM. Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control. The Oncologist. 2003;8:187-98. 27. Han HS, Park JC, Park SY et al. A prospective multicenter study evaluating secondary adrenal suppression after antiemetic dexamethasone therapy in cancer patients receiving chemotherapy: A Korean South West Oncology Group study. The Oncologist 2015;20:1432-9. 28. Nakamura M, Ishiguro A, Muranaka T et al. A prospective observational study on effect of short-term periodic steroid premedication on bone metabolism in gastrointestinal cancer (ESPRESSO-01). The Oncologist 2017;22:592-600. 29. Gralla RJ, Itri LM, Pisko SE et al. Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 1981;305:905-9. 30. Aapro MS, Plezia PM, Alberts DS et al. Double-blind crossover study of the antiemetic efficacy of high-dose dexamethasone versus high-dose metoclopramide. J Clin Oncol 1984;2:46671. 31. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31:11-9.
RkJQdWJsaXNoZXIy MjY0ODMw